Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
Neuronostatin-13 (human, canine, porcine) is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function.
ln Vitro |
Neuronostatin-13 human is a 13-amino acid peptide hormone that is essential for controlling cardiac and hormonal processes. It is encoded by the somatostatin gene. In comparison to islets treated with control medium alone, treatment with Neuronostatin-13 human (1,000 nM) improves low-glucose-induced glucagon release. When compared to control cells treated with vehicle, the accumulation of glucagon mRNA is significantly increased after a one-hour treatment with Neuronostatin-13 human. When αTC1-9 α-cells are treated with 100 nM Neuronostatin-13 human, phosphorylated PKA levels rise between 30 and 40 minutes[1].
|
---|---|
ln Vivo |
In the rat model, infusion of Neuronostatin-13 human postpones the clearance of glucose, resulting in notably elevated blood glucose levels in animals treated with Neuronostatin-13 human at 1 and 10 minutes after intra-arterial injection of a glucose bolus[1]. Heart rate significantly decreases after 3, 6, and 12 hours with Neuronostatin-13 human challenge, according to chocardiographic assessment. Additionally, between 6 and 12 hours after a Neuronostatin-13 human challenge, Neuronostatin-13 human treatment significantly reduces left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD). The effect reaches its baseline 18 hours later[2].
|
References |
[1]. Salvatori AS, et al. Neuronostatin inhibits glucose-stimulated insulin secretion via direct action on the pancreatic α-cell. Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1257-63.
[2]. Zhu X, et al. Neuronostatin attenuates myocardial contractile function through inhibition of sarcoplasmic reticulum Ca2+-ATPase in murine heart. Cell Physiol Biochem. 2014;33(6):1921-32 |
Molecular Formula |
C64H110N20O16
|
---|---|
Molecular Weight |
1415.68261384964
|
CAS # |
1096485-24-3
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C([C@H](CC(C)C)NC([C@@H](CC1C=CC=CC=1)NC([C@H](CCC(N)=O)NC([C@H](CCC/N=C(\N)/N)NC([C@H](CC(C)C)N)=O)=O)=O)=O)N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)C)=O)C)=O)C)=O)C)=O)CC(C)C)=O)=O)CCCCN)=O)CCC(N)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~25 mg/mL (~17.66 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (70.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.7064 mL | 3.5319 mL | 7.0637 mL | |
5 mM | 0.1413 mL | 0.7064 mL | 1.4127 mL | |
10 mM | 0.0706 mL | 0.3532 mL | 0.7064 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.